Evidence map›Paper›PMID 29527532›Full record

ArticleMatters2016

MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers.

Sami Ventelä, Juho-Antti Mäkelä, Rosalie C Sears, Jorma Toppari, Jukka Westermarck

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Matters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sami VenteläDepartment of Physiology, University of Turku; Department of Molecular and Medical Genetics and Knight Cancer Institute, Oregon Health and Science University; Centre for Biotechnology and Department of Pathology, University of Turku.
Juho-Antti MäkeläDepartment of Physiology, University of Turku; Department of Molecular and Medical Genetics and Knight Cancer Institute, Oregon Health and Science University; Centre for Biotechnology and Department of Pathology, University of Turku.
Rosalie C SearsDepartment of Physiology, University of Turku; Department of Molecular and Medical Genetics and Knight Cancer Institute, Oregon Health and Science University; Centre for Biotechnology and Department of Pathology, University of Turku.
Jorma ToppariDepartment of Physiology, University of Turku; Department of Molecular and Medical Genetics and Knight Cancer Institute, Oregon Health and Science University; Centre for Biotechnology and Department of Pathology, University of Turku.
Jukka WestermarckDepartment of Physiology, University of Turku; Department of Molecular and Medical Genetics and Knight Cancer Institute, Oregon Health and Science University; Centre for Biotechnology and Department of Pathology, University of Turku.
University of Turku · FI

Funding

The Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0M
NCI NIH HHS R01 CA196228
6 · The paper itself

Abstract

High MYC expression is linked to proliferative activity in most normal tissues and in cancer. MYC also supports self-renewal and proliferation of many types of tissue progenitor cells. Cancerous inhibitor of PP2A (CIP2A) promotes MYC phosphorylation and activity during intestinal crypt regeneration

Identifiers

PMID29527532
PMCPMC5843371
OpenAlexW2342375240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.